- You are here:
- Home »
- Blog »
- prostate cancer »
- Testosterone Prevents Prostate Cancer???
Testosterone Prevents Prostate Cancer???
Wait, what? Testosterone prevents prostate cancer??? For as long as I can remember, I thought that testosterone causes prostate cancer. According to both the video and the info linked below, the relationship between testosterone and prostate cancer is…complicated.
There are times when men should reduce their testosterone and other times when they should increase their testosterone. Therefore, you should talk to your doctor about testosterone and your specific situation.
But for me…an autologous stem cell transplant for my blood cancer reduced my testosterone levels. So I supplemented with it. I focus on my prostate, bone, heart, and brain health. I’m a mixed bag when it comes to the issue of testosterone.
The role of testosterone in prostate cancer
Have you been diagnosed with prostate cancer? Or you are considering TNT aka testosterone replacement therapy? Scroll down the page, post a question or comment, and I will reply to you ASAP.
Thanks,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study
Abstract
We sought to understand the relationship between hypogonadism and testosterone replacement therapy (TRT) in hypogonadal men on the risk of developing localized and metastatic prostate cancer. We used the Merative MarketScan database of commercial claims encounters to identify men diagnosed with hypogonadism. These men were matched to eugonadal men who served as controls.
Multivariate negative binomial regression analysis of prostate cancer diagnoses, hypogonadism, and TRT in hypogonadal men adjusting for various known confounding factors was used to understand the impact of hypogonadism and TRT on prostate cancer risk.
We identified 3,222,904 men who met inclusion criteria, of which 50% were diagnosed with hypogonadism (1,611,452) and each were matched to a control (1,611,452). The incidence of prostate cancer was 2.16%, 1.55%, and 1.99% in eugonadal controls, hypogonadal men on TRT, and hypogonadal men without TRT, respectively (p < 0.001).
Untreated hypogonadism was independently associated with a decreased risk of localized prostate cancer (IRR 0.46, 95% CI 0.43-0.50, p < 0.001) compared to eugonadal controls. Hypogonadal men on TRT also had a significantly decreased risk of localized prostate cancer (IRR 0.49, 95% CI 0.45-0.53, p < 0.001).
Furthermore, hypogonadal men on TRT (IRR 0.21, 95% CI 0.19-0.24, p < 0.001) or without TRT (IRR 0.20, 95% CI 0.18-0.22, p < 0.001) both had significantly decreased risk of metastatic prostate cancer, respectively.
Our population-based analysis suggests that untreated hypogonadism in men is associated with a 50% decreased incidence of localized prostate cancer and an 80% decreased incidence of metastatic prostate cancer.
TRT in hypogonadal men was also associated with a decreased risk of subsequent prostate cancer. Further research is needed to better understand the relationship between hypogonadism and TRT in hypogonadal men on the risk of subsequent prostate cancer.
Could More Testosterone be the Hidden Key to Fighting Prostate Cancer?
Androgen deprivation therapy (ADT) has been the bedrock of treatment for advanced prostate cancer for more than half a century. But investigators at Johns Hopkins are rethinking it – in a way that sounds counterintuitive – and driving new approaches to tackle treatment resistance. They’re discovering that shaking up prostate cancer with high-dose testosterone makes it more vulnerable to other treatments.
ADT slows prostate cancer’s progress by shutting off testosterone. Eventually, however, cancer adapts to this new environment and PSA levels start to rise; this stage is called castrate-resistant prostate cancer (CRPC). ADT is not a curative treatment, and long-term ADT causes significant side effects, including fatigue, hot flashes, weight gain, and loss of sexual function.
Testosterone prevents prostate cancer Testosterone prevents prostate cancer Testosterone prevents prostate cancer